CHRS
Coherus Oncology, Inc.
$1.42
-2.07%
$219.0M
No data for this timeframe.
Vol
Market Cap$219.0M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders8 funds
Inst. Value$17.2M
Inst. Activity4 buys / 0 sells
SEC Reports5
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001512762·Prev Close $1.45
Recent Activity
Jun 5, 2026
Insider
Satvat Ali J. sold 60,000 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
Satvat Ali J. sold 30,000 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
Newcomer Lee Nisley sold 60,000 shares
Director @ $0.00 ($0.00)
May 29, 2026
short_volume
Short Volume: CHRS — 60.4% short (0.4M / 0.6M)
Short: 387,656 | Exempt: 6,215 | TRF Vol: 642,328 | Short Ratio: 60.4% | Off-exchange volume (dark p
May 28, 2026
SEC
Coherus Oncology's 2026 annual meeting was adjourned from May 27 to May 29, 2026, to count remaining votes on Proposal N
DEFA14A — Impact 4/10
May 11, 2026
SEC
Coherus reported Q1 2026 GAAP EPS of -$0.27, beating consensus of -$0.29 by 6.9%, while revenue of $12.3M missed the $14
PRESS-RELEASE — Impact 6/10
May 5, 2026
SEC
Coherus Oncology filed definitive additional proxy materials (DEFA14A) reminding employees to vote at the May 27, 2026 a
DEFA14A — Impact 2/10
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
503,875 shares ($715.5K)
Price Targets
$7.80
+449.3% upside
Strong Buy
Current $1.42
Low $4.00
Median $7.00
High $12.00
5 analysts
$4.00
$12.00
Analyst Ratings
5Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Guggenheim | INITIATE | Buy |
| Jan 22, 2026 | Oppenheimer | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.12 ▲ +20.7% | $-0.31 — $0.08 | 66% YoY | 2 |
| Next Q | $-0.23 ▲ +10.0% | $-0.29 — $-0.16 | 32% YoY | 2 |
| Current FY | $-0.74 ▲ +5.7% | $-1.23 — $-0.26 | 45% YoY | 2 |
| Next FY | $-1.02 ▼ -25.9% | $-1.02 — $-1.02 | -37% YoY | 1 |
Latest Reports
NEUTRAL
DEFA14A
4/10
Coherus Oncology's 2026 annual meeting was adjourned from May 27 to May 29, 2026, to count remaining votes on Proposal N
May 28, 2026
MIXED
PRESS-RELEASE
6/10
Coherus reported Q1 2026 GAAP EPS of -$0.27, beating consensus of -$0.29 by 6.9%, while revenue of $12.3M missed the $14
May 11, 2026
BULLISH
Press
8/10
Coherus Oncology reported strong revenue growth for LOQTORZI, with full-year 2025 net revenue reaching $42.2 million, up
Mar 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $14.2M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.3M | NEW |
| TWO SIGMA INVESTMENTS, LP | $715.5K | DOUBLED |
| MORGAN STANLEY | $352.7K | NEAR_EXIT |
| RENAISSANCE TECHNOLOGIES LLC | $195.8K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Satvat Ali | A | $0.00 |
| Jun 5, 2026 | Satvat Ali | A | $0.00 |
| Jun 5, 2026 | Newcomer Lee | A | $0.00 |
| Jun 5, 2026 | Newcomer Lee | A | $0.00 |
| Jun 5, 2026 | Karachun Rita | A | $0.00 |
8 institutional holders with $17.2M total value (12,091,822 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, TWO. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 10,028,893 | $14.2M | 82.9% | — |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 935,239 | $1.3M | 7.7% | NEW |
| 3 | TWO SIGMA INVESTMENTS, LP | 503,875 | $715.5K | 4.2% | DOUBLED +1310.9% |
| 4 | MORGAN STANLEY | 248,394 | $352.7K | 2.1% | NEAR_EXIT -90.4% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 137,900 | $195.8K | 1.1% | DOUBLED +472.2% |
| 6 | WELLS FARGO & COMPANY/MN | 117,975 | $167.5K | 1.0% | ADD +55.1% |
| 7 | BANK OF AMERICA CORP /DE/ | 111,703 | $158.6K | 0.9% | ADD +47.4% |
| 8 | FMR LLC | 7,843 | $11.1K | 0.1% | ADD +28.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 35,712 | 503,875 | +1310.9% | $715.5K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 24,100 | 137,900 | +472.2% | $195.8K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 76,073 | 117,975 | +55.1% | $167.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 75,803 | 111,703 | +47.4% | $158.6K | 2025-Q4 |
| UBS Group AG | ADD | 574,531 | 795,941 | +38.5% | $1.3M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 35,712 | — | $58.6K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 522,925 | 24,100 | -95.4% | $39.5K | 2025-Q3 |
| FMR LLC | ADD | 6,492 | 8,322 | +28.2% | $13.6K | 2025-Q3 |
| UBS Group AG | ADD | 368,951 | 574,531 | +55.7% | $420.0K | 2025-Q2 |
| FMR LLC | TRIM | 24,606 | 6,492 | -73.6% | $4.7K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 510,628 | — | $412.1K | 2025-Q1 |
| UBS Group AG | TRIM | 708,999 | 368,951 | -48.0% | $297.7K | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 2,111,302 | 202,948 | -90.4% | $163.8K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 307,300 | 106,200 | -65.4% | $85.7K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 134,138 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 826,977 | 2,111,302 | +155.3% | $2.9M | 2024-Q4 |
| UBS Group AG | DOUBLED | 173,169 | 708,999 | +309.4% | $978.4K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 2,926,008 | 307,300 | -89.5% | $424.1K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 46,693 | 61,830 | +32.4% | $85.3K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 432,068 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 964,327 | — | $1.0M | 2024-Q3 |
| MORGAN STANLEY | TRIM | 1,556,850 | 826,977 | -46.9% | $860.1K | 2024-Q3 |
9 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Satvat Ali J. | Director | A | 60,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Satvat Ali J. | Director | A | 30,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Newcomer Lee Nisley | Director | A | 60,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Newcomer Lee Nisley | Director | A | 30,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Karachun Rita A | Director | A | 60,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Karachun Rita A | Director | A | 30,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Ryan Michael Lee | Director | A | 60,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Ryan Michael Lee | Director | A | 30,000 | $0.00 | $0.00 |
| Jun 5, 2026 | O'Donnell-Tormey Jill | Director | A | 60,000 | $0.00 | $0.00 |
| Jun 5, 2026 | O'Donnell-Tormey Jill | Director | A | 30,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Wahlstrom Mats | Director | A | 30,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Wahlstrom Mats | Director | A | 60,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Newton Charles W. | Director | A | 60,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Newton Charles W. | Director | A | 30,000 | $0.00 | $0.00 |
| May 29, 2026 | McMichael Bryan J | Chief Financial Officer | A | 100,000 | $0.00 | $0.00 |
| May 29, 2026 | McMichael Bryan J | Chief Financial Officer | D | 100,000 | $0.00 | $0.00 |
| May 29, 2026 | Lanfear Dennis M | President & CEO | A | 200,000 | $0.00 | $0.00 |
| May 29, 2026 | Lanfear Dennis M | President & CEO | D | 200,000 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 3 neutral. Avg impact: 3.8/10.
NEUTRAL
DEFA14A
4/10
Coherus Oncology's 2026 annual meeting was adjourned from May 27 to May 29, 2026, to count remaining
May 28, 2026
MIXED
PRESS-RELEASE
6/10
Coherus reported Q1 2026 GAAP EPS of -$0.27, beating consensus of -$0.29 by 6.9%, while revenue of $
May 11, 2026
NEUTRAL
DEFA14A
2/10
Coherus Oncology filed definitive additional proxy materials (DEFA14A) reminding employees to vote a
May 5, 2026
NEUTRAL
PRESS-RELEASE
1/10
Coherus Oncology issued a press release announcing that its Q1 2026 financial results will be releas
May 4, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly i
Feb 28, 2026
Current analyst consensus: Strong Buy (85% buy). Based on 13 analysts: 5 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.80 mean target
+449.3% upside
Strong Buy (1.43)
$4.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $1.42 |
| Target Low | $4.00 |
| Target Mean | $7.80 |
| Target Median | $7.00 |
| Target High | $12.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.43) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.12 | $-0.31 | $0.08 | 66.2% | +20.7% | 2↑ 0↓ | $0.0B | 99.4% | 2 |
| Next Q 2026-09-30 |
$-0.23 | $-0.29 | $-0.16 | 31.8% | +10.0% | 2↑ 0↓ | $0.0B | 38.8% | 2 |
| Current FY 2026-12-31 |
$-0.74 | $-1.23 | $-0.26 | 45.2% | +5.7% | 1↑ 1↓ | $0.1B | 73.2% | 2 |
| Next FY 2027-12-31 |
$-1.02 | $-1.02 | $-1.02 | -36.9% | -25.9% | 1↑ 0↓ | $0.1B | 37.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.115 | |
| 7d ago | $0.080 | -0.195 |
| 30d ago | $-0.145 | +0.030 |
| 60d ago | $-0.145 | +0.030 |
| 90d ago | $-0.310 | +0.195 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Guggenheim | INITIATE | — | Buy |
| Jan 22, 2026 | Oppenheimer | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Apr 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Feb 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Jan 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 29, 2026
short_volume
Short Volume: CHRS — 60.4% short (0.4M / 0.6M)
Short: 387,656 | Exempt: 6,215 | TRF Vol: 642,328 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: CHRS — 55.7% short (0.3M / 0.6M)
Short: 317,315 | Exempt: 1,468 | TRF Vol: 569,492 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: CHRS — 69.9% short (0.4M / 0.6M)
Short: 439,761 | Exempt: 185 | TRF Vol: 628,833 | Short Ratio: 69.9% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: CHRS — 69.0% short (0.4M / 0.6M)
Short: 441,504 | Exempt: 2,812 | TRF Vol: 639,964 | Short Ratio: 69.0% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: CHRS — 62.0% short (0.6M / 0.9M)
Short: 589,138 | Exempt: 5,115 | TRF Vol: 949,904 | Short Ratio: 62.0% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: CHRS — 66.2% short (0.8M / 1.2M)
Short: 797,034 | Exempt: 51,337 | TRF Vol: 1,204,299 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: CHRS — 63.4% short (1.2M / 1.9M)
Short: 1,178,676 | Exempt: 95,421 | TRF Vol: 1,859,252 | Short Ratio: 63.4% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>– LOQTORZI<sup>®</sup> net revenue of $11.8 million in Q1 2026 –</em></p>
May 11, 2026
earnings_calendar
CHRS Q1 2026 Earnings Scheduled — 2026-05-11
May 4, 2026
earnings
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
<p align="left">REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc</strong>. (Nasdaq: CHRS), today announced that
Apr 30, 2026
earnings_calendar
CHRS Q1 2026 Earnings Scheduled — 2026-04-30
Mar 30, 2026
Clinical Trial
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Phase Phase 2 — COMPLETED
Mar 25, 2026
short_volume
Short Volume: CHRS — 66.7% short (0.8M / 1.2M)
Short: 798,529 | Exempt: 244 | TRF Vol: 1,197,531 | Short Ratio: 66.7% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
short_volume
Short Volume: CHRS — 69.9% short (1.0M / 1.5M)
Short: 1,032,285 | Exempt: 420 | TRF Vol: 1,477,227 | Short Ratio: 69.9% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_volume
Short Volume: CHRS — 61.5% short (0.3M / 0.6M)
Short: 347,756 | Exempt: 11 | TRF Vol: 565,227 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
Mar 9, 2026
earnings
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
<p align="center"><em>– LOQTORZI<sup>®</sup> net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 –</em></p>